TMC435-TiDP16-C212 - Trial of TMC435 in Genotype 1 Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021337-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

- To evaluate the safety and tolerability of TMC435 in combination with pegylated interferon alpha-2a (PegIFNα- 2a)/ribavirin (RBV) in HCV genotype-1 infected subjects, co-infected with HIV-1. - To evaluate the proportion of subjects with sustained virologic response (SVR) 24 weeks after the planned end of treatment (SVR24).


Critère d'inclusion

  • Hepatitis C and co-infected with HIV